

Media Release

Zug, 5 January 2026

Ad hoc announcement pursuant to Art. 53 LR

HBM Healthcare Investments once again delivered strong value growth in the 2025 calendar year despite currency headwind

HBM Healthcare Investments, an investment company specialising in the healthcare sector, looks back on a successful 2025 calendar year. The net asset value (NAV) increased by 14.8 percent in Swiss francs (31.4 percent in US Dollars) over the course of the year, while the share price recorded a disproportionate gain of 33.0 percent.

In comparison, the relevant market indices performed as follows in Swiss francs: NASDAQ Biotechnology Index (NBI): +15.6%, SPDR S&P Biotech (XBI): +18.8%, MSCI World Healthcare Index: +0.9%.

HBM's investment strategy, based on a balanced and broadly diversified portfolio structure comprising private and publicly listed companies, once again proved successful. The value creation was roughly evenly split between the two asset classes. Among private companies, the successful exits of Swixx Biopharma and Dren Bio made a significant contribution to the positive performance. Publicly listed companies benefited from renewed investor interest in the biotechnology sector during the second half of the year, driven by acquisitions and strong clinical data.

Currency effects hurt the annual result, due to the exceptionally strong appreciation of the Swiss franc against key investment currencies: USD: -12.7%, EUR: -0.9%, CNY: -8.8%, INR: -17.0%.

Profit of CHF 286 million expected for the first nine months of the 2025/2026 financial year

In the first nine months of the 2025/2026 financial year, NAV rose by 18.0%. As a result, the company expects a profit of around CHF 286 million for this period (previous year: profit of CHF 66 million).

The figures presented are preliminary, based on the current status of the closing process. The final nine-month results will be published in the quarterly report on 23 January 2026.

Contact us

For further information, please contact Dr Andreas Wicki on +41 41 710 75 77, or at andreas.wicki@hbmhealthcare.com

About HBM Healthcare Investments

HBM Healthcare Investments invests in the healthcare sector. The Company holds and manages an international portfolio of promising companies in the human medicine, biotechnology, medical technology and diagnostics sectors and related areas. Many of these companies have their lead products already available on the market or at an advanced stage of development. The portfolio companies are closely tracked and actively guided in their strategic direction. This is what makes HBM Healthcare Investments an interesting alternative to investments in big pharma and biotechnology companies. HBM Healthcare Investments has an international shareholder base and is listed on SIX Swiss Exchange (ticker: HBMN).

Disclaimer

The publication is for information purposes only and does not constitute an offer to sell or a solicitation to buy or subscribe for securities. This news release does not constitute a prospectus within the meaning of Art. 35ff FinSA, or securities prospectus in the sense of the German securities prospectus law. This news release and the information contained therein is not intended for distribution to the United States of America (USA) or within the USA and may not be distributed or forwarded to U.S. persons (including legal persons) or to publications with a general distribution in the USA. This news release is not an offer or solicitation to buy securities in the United States. HBM Healthcare Investments Ltd's securities were not issued in accordance with the U.S. securities laws, and may not be sold, offered for sale, or delivered in the U.S. or to U.S. individuals without prior registration or without a registration exemption. Some information quoted was obtained from external sources HBM considers to be reliable. HBM cannot guarantee the adequacy, accuracy, timeliness or completeness of or be held responsible or liable for errors of fact regarding such data and information obtained from third parties, and this data may change with market conditions.